MX2023001615A - Genoterapia con placofilina-2 (pkp2) mediante el uso de vector de aav. - Google Patents
Genoterapia con placofilina-2 (pkp2) mediante el uso de vector de aav.Info
- Publication number
- MX2023001615A MX2023001615A MX2023001615A MX2023001615A MX2023001615A MX 2023001615 A MX2023001615 A MX 2023001615A MX 2023001615 A MX2023001615 A MX 2023001615A MX 2023001615 A MX2023001615 A MX 2023001615A MX 2023001615 A MX2023001615 A MX 2023001615A
- Authority
- MX
- Mexico
- Prior art keywords
- pkp2
- plakophilin
- gene therapy
- vector
- promoter
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 3
- 108010057275 Plakophilins Proteins 0.000 title abstract 2
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 102000003753 Plakophilins Human genes 0.000 title 1
- 210000000234 capsid Anatomy 0.000 abstract 3
- 102100030348 Plakophilin-2 Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 101000583179 Homo sapiens Plakophilin-2 Proteins 0.000 abstract 1
- 102000004987 Troponin T Human genes 0.000 abstract 1
- 108090001108 Troponin T Proteins 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000013608 rAAV vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se proporciona una genoterapia para PKP2 (Placofilina-2), por ejemplo, mediante el uso de un vector de virus adenoasociado (AAV). El promotor del vector puede ser un promotor MHCK7 o un promotor de troponina cardíaca T (HTNNT2). La cápside puede ser una cápside de AAV9 o AAVrh74 o variante funcional de esta. Pueden usarse otros promotores o cápsides. Se proporcionan además métodos de tratamiento, tales como por administración intravenosa, intracoronaria, intracarótida o intracardíaca del vector de rAAV, y otras composiciones y métodos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063063032P | 2020-08-07 | 2020-08-07 | |
PCT/US2021/045220 WO2022032226A1 (en) | 2020-08-07 | 2021-08-09 | Plakophilin-2 (pkp2) gene therapy using aav vector |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023001615A true MX2023001615A (es) | 2023-03-08 |
Family
ID=80118582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023001615A MX2023001615A (es) | 2020-08-07 | 2021-08-09 | Genoterapia con placofilina-2 (pkp2) mediante el uso de vector de aav. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20220168447A1 (es) |
EP (1) | EP4192487A1 (es) |
JP (1) | JP2023538519A (es) |
KR (1) | KR20230043869A (es) |
CN (1) | CN116194154A (es) |
AU (1) | AU2021320902A1 (es) |
BR (1) | BR112023001852A2 (es) |
CA (1) | CA3185267A1 (es) |
IL (1) | IL300263A (es) |
MX (1) | MX2023001615A (es) |
WO (1) | WO2022032226A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL300263A (en) | 2020-08-07 | 2023-03-01 | Spacecraft Seven Llc | Plakophilin-2 (PKP2) gene therapy using an AAV vector |
US11781156B2 (en) * | 2020-10-09 | 2023-10-10 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy methods and compositions |
KR20230159471A (ko) * | 2021-03-19 | 2023-11-21 | 유씨엘 비즈니스 리미티드 | 우심실 부정맥성 심근병증의 유전자 치료 조성물 및 치료 |
EP4367251A1 (en) * | 2021-07-08 | 2024-05-15 | Tenaya Therapeutics, Inc. | Optimized expression cassettes for gene therapy |
WO2023200736A2 (en) * | 2022-04-11 | 2023-10-19 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy treatment methods |
WO2023200742A2 (en) * | 2022-04-11 | 2023-10-19 | Tenaya Therapeutics, Inc. | Capsids for plakophillin-2 gene therapy |
WO2024064863A2 (en) * | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
WO1989002469A2 (en) | 1987-09-17 | 1989-03-23 | Massachusetts Institute Of Technology | Human erythroid-specific transcriptional enhancer |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
EP0648271B1 (en) | 1991-08-20 | 2003-04-16 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
JP3866760B2 (ja) | 1993-02-22 | 2007-01-10 | ザ ロックフェラー ユニバーシティ | 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産 |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
US6027721A (en) | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
US7994278B1 (en) | 1999-08-06 | 2011-08-09 | Nobel Biosciences Llc | Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
AU784910B2 (en) | 1999-10-12 | 2006-07-27 | Centre National De La Recherche Scientifique | Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA |
CA2406743A1 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
US6627442B1 (en) | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
US20070037165A1 (en) * | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
GB0024550D0 (es) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
CA2456169C (en) | 2001-08-02 | 2012-05-22 | Didier Trono | Methods and compositions relating to improved lentiviral vector production systems |
AU2002343458B2 (en) | 2001-10-02 | 2008-03-20 | Institut Clayton De La Recherche | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
EP1310571B1 (en) | 2001-11-13 | 2006-02-15 | The Trustees of The University of Pennsylvania | A Method of identifying unknown adeno-associated virus (AVV) sequences and a kit for the method |
DE60329747D1 (de) | 2002-05-02 | 2009-12-03 | Univ Rochester | Vektoren mit beiden isoformen von beta-hexosaminidase |
AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
WO2004015106A1 (en) | 2002-08-12 | 2004-02-19 | UNIVERSITé DE SHERBROOKE | Methods to reprogram splice site selection in pre-messenger rnas |
DK1616012T3 (da) | 2003-04-24 | 2008-04-21 | San Raffaele Centro Fond | Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf |
US7960100B1 (en) * | 2004-04-30 | 2011-06-14 | Celera Corporation | Colon cancer targets and uses thereof |
JP2007054069A (ja) | 2005-08-24 | 2007-03-08 | Medizinische Hochschule Hannover | 自己不活性化レトロウイルスベクター |
US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US9109012B2 (en) | 2007-05-29 | 2015-08-18 | Nature Technology Corporation | Vectors and method for genetic immunization |
ES2615180T3 (es) | 2007-07-14 | 2017-06-05 | University Of Iowa Research Foundation | Métodos y composiciones para el tratamiento de enfermedades cerebrales |
EP2424887B1 (en) | 2009-04-30 | 2015-09-30 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inducible interleukin-12 |
DE102009021592A1 (de) | 2009-05-15 | 2010-11-18 | Medizinische Hochschule Hannover | ASLV-Vektorsystem |
US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
RU2653444C2 (ru) | 2012-02-17 | 2018-05-08 | Дзе Чилдрен'З Хоспитал Оф Филадельфия | Композиции вектора aav и способы переноса генов в клетки, органы и ткани |
EP3494997B1 (en) | 2012-07-25 | 2019-09-18 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
EP2792742A1 (en) | 2013-04-17 | 2014-10-22 | Universitätsklinikum Hamburg-Eppendorf (UKE) | Gene-therapy vectors for treating cardiomyopathy |
WO2015038958A1 (en) | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Selective recovery |
GB201318347D0 (en) | 2013-10-16 | 2013-11-27 | Ucl Business Plc | Retroviral vectors |
CN105745326A (zh) | 2013-10-24 | 2016-07-06 | 优尼科Ip有限公司 | 用于基因治疗神经疾病的aav-5假型载体 |
CA2947466A1 (en) | 2014-05-01 | 2015-11-05 | University Of Washington | In vivo gene engineering with adenoviral vectors |
CA2946593A1 (en) | 2014-05-02 | 2015-11-05 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
WO2015188191A1 (en) | 2014-06-06 | 2015-12-10 | Wong Wilson W | Dna recombinase circuits for logical control of gene expression |
WO2015196179A1 (en) | 2014-06-20 | 2015-12-23 | University Of Florida Research Foundation, Inc. | Methods of packaging multiple adeno-associated virus vectors |
MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
US10350245B2 (en) | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
PT3268024T (pt) | 2015-03-10 | 2020-12-09 | Univ Columbia | Construtos de vetor viral recombinante glut1 adeno associado e métodos relacionados para restaurar a expressão de glut1 |
CA2985081A1 (en) | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-influenza antibodies and methods of use thereof |
MX2018005886A (es) | 2015-11-11 | 2018-08-15 | Intrexon Corp | Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias. |
IL259842B (en) | 2015-12-11 | 2022-08-01 | California Inst Of Techn | Targeted peptides for the targeting of adeno-associated viruses -aavs- |
CN116440292A (zh) | 2016-01-19 | 2023-07-18 | 加利福尼亚大学董事会 | Danon病和其它自噬障碍的治疗方法 |
WO2017136536A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
WO2017184903A1 (en) | 2016-04-20 | 2017-10-26 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Compositions and methods for enhanced gene expression of pklr |
SG11201901718VA (en) | 2016-09-08 | 2019-03-28 | Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas | Gene therapy for patients with fanconi anemia |
US11338046B2 (en) | 2016-09-30 | 2022-05-24 | Esteve Pharmaceuticals, S.A. | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses |
US20180326022A1 (en) * | 2017-04-21 | 2018-11-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for improving heart function and treating heart failure |
WO2018201065A1 (en) | 2017-04-27 | 2018-11-01 | Fred Hutchinson Cancer Research Center | Therapeutic formulations containing cd34+ stem cells derived from negative selection |
EP3622062A4 (en) | 2017-05-10 | 2020-10-14 | The Regents of the University of California | DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9 |
JP7418826B2 (ja) | 2017-09-20 | 2024-01-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 不整脈源性右心室心筋症における電気的機能及び心臓機能並びに心構造を回復するための遺伝子療法戦略 |
US20200308582A1 (en) * | 2017-10-12 | 2020-10-01 | Universität Heidelberg | Kcnk3-based gene therapy of cardiac arrhythmia |
CA3076253A1 (en) | 2017-10-16 | 2019-04-25 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicaso.A., M.P. | Lentiviral vectors for delivery of pklr to treat pyruvate kinase deficiency |
WO2019200167A1 (en) | 2018-04-11 | 2019-10-17 | Rocket Pharmaceuticals, Ltd. | Compositions and methods for stem cell transplant |
EP3784288A1 (en) | 2018-04-27 | 2021-03-03 | Universität Heidelberg | Modified aav capsid polypeptides for treatment of muscular diseases |
WO2019210325A1 (en) | 2018-04-27 | 2019-10-31 | Rocket Pharmaceuticals, Ltd. | Gene therapy for cns degeneration |
EP3820537A4 (en) | 2018-07-12 | 2022-04-13 | Spacecraft Seven, LLC | GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE |
CN112888777A (zh) | 2018-07-30 | 2021-06-01 | 能源环境和技术研究中心O.A., M.P. | 用于造血细胞的基因修饰的方法 |
AU2019319976A1 (en) | 2018-08-10 | 2021-01-28 | Regenxbio Inc. | Scalable method for recombinant AAV production |
BR112021002765A2 (pt) | 2018-08-16 | 2021-07-20 | Spacecraft Seven, Llc | métodos de produção para vetores virais |
WO2020152210A1 (en) | 2019-01-22 | 2020-07-30 | Koninklijke Nederlandse Akademie Van Wetenschappen | Tfap2 inhibition for treating cardiac disease involving fibro-fatty replacement |
CA3128514A1 (en) * | 2019-02-12 | 2020-08-20 | Spacecraft Seven, Llc | Gene therapy vectors for treatment of danon disease |
CA3137700A1 (en) | 2019-05-23 | 2020-11-26 | Brian Beard | Gene therapy vectors for infantile malignant osteopetrosis |
KR20220066914A (ko) * | 2019-09-20 | 2022-05-24 | 유씨엘 비즈니스 리미티드 | 부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료 |
WO2021163357A2 (en) | 2020-02-13 | 2021-08-19 | Tenaya Therapeutics, Inc. | Gene therapy vectors for treating heart disease |
JPWO2021187380A1 (es) | 2020-03-16 | 2021-09-23 | ||
AU2021259422A1 (en) | 2020-04-20 | 2022-12-08 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
US20230174994A1 (en) | 2020-05-20 | 2023-06-08 | Spacecraft Seven, Llc | Engineered parkin and uses thereof |
WO2022017630A1 (en) | 2020-07-23 | 2022-01-27 | Ucl Business Ltd | GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF |
IL300185A (en) | 2020-08-05 | 2023-03-01 | Spacecraft Seven Llc | Adeno-associated viral vector for GLUT1 expression and uses thereof |
JP2023536618A (ja) | 2020-08-05 | 2023-08-28 | スペースクラフト セブン リミテッド ライアビリティ カンパニー | Csrp3(システイン及びグリシンリッチタンパク質3)遺伝子治療 |
IL300263A (en) | 2020-08-07 | 2023-03-01 | Spacecraft Seven Llc | Plakophilin-2 (PKP2) gene therapy using an AAV vector |
BR112023006305A2 (pt) | 2020-10-09 | 2023-05-09 | Tenaya Therapeutics Inc | Métodos e composições de terapia gênica com placofilina-2 |
CA3201247A1 (en) | 2020-12-07 | 2022-06-16 | Gaurav Shah | Treatment of danon disease |
KR20230159471A (ko) | 2021-03-19 | 2023-11-21 | 유씨엘 비즈니스 리미티드 | 우심실 부정맥성 심근병증의 유전자 치료 조성물 및 치료 |
KR20230170686A (ko) | 2021-04-12 | 2023-12-19 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 부정맥유발 우심실 심근병증에 대한 유전자 치료법 |
EP4367251A1 (en) | 2021-07-08 | 2024-05-15 | Tenaya Therapeutics, Inc. | Optimized expression cassettes for gene therapy |
-
2021
- 2021-08-09 IL IL300263A patent/IL300263A/en unknown
- 2021-08-09 AU AU2021320902A patent/AU2021320902A1/en active Pending
- 2021-08-09 CA CA3185267A patent/CA3185267A1/en active Pending
- 2021-08-09 MX MX2023001615A patent/MX2023001615A/es unknown
- 2021-08-09 JP JP2023507876A patent/JP2023538519A/ja active Pending
- 2021-08-09 EP EP21853198.6A patent/EP4192487A1/en active Pending
- 2021-08-09 CN CN202180058096.5A patent/CN116194154A/zh active Pending
- 2021-08-09 WO PCT/US2021/045220 patent/WO2022032226A1/en active Search and Examination
- 2021-08-09 KR KR1020237003609A patent/KR20230043869A/ko unknown
- 2021-08-09 BR BR112023001852A patent/BR112023001852A2/pt unknown
-
2022
- 2022-02-11 US US17/670,390 patent/US20220168447A1/en not_active Abandoned
- 2022-02-11 US US17/670,389 patent/US11883506B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP4192487A1 (en) | 2023-06-14 |
WO2022032226A1 (en) | 2022-02-10 |
US20220168447A1 (en) | 2022-06-02 |
JP2023538519A (ja) | 2023-09-08 |
CN116194154A (zh) | 2023-05-30 |
US20220168446A1 (en) | 2022-06-02 |
AU2021320902A1 (en) | 2023-04-06 |
KR20230043869A (ko) | 2023-03-31 |
BR112023001852A2 (pt) | 2023-02-23 |
CA3185267A1 (en) | 2022-02-10 |
IL300263A (en) | 2023-03-01 |
US11883506B2 (en) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001615A (es) | Genoterapia con placofilina-2 (pkp2) mediante el uso de vector de aav. | |
MX2023000994A (es) | Genoterapia con csrp3 (proteina 3 rica en cisteina y glicina). | |
US11344608B2 (en) | Factor IX gene therapy | |
PH12020550706A1 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
EP4218828A3 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
TW201706412A (zh) | Fabry氏病基因療法 | |
JP2019513389A5 (es) | ||
BR112021020054A2 (pt) | Capsídeos de vírus adeno-associado (aav) e composições contendo os mesmos | |
RU2018136611A (ru) | Генная терапия для лечения гемофилии a | |
WO2022040527A3 (en) | Adeno-associated virus compositions having preferred expression levels | |
MX2022009883A (es) | Vectores de genoterapia para tratar enfermedades cardíacas. | |
MX2021013364A (es) | Composiciones utiles para el tratamiento de la enfermedad de pompe. | |
WO2021163357A3 (en) | Gene therapy vectors for treating heart disease | |
PE20211819A1 (es) | Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn | |
MX2023001863A (es) | Nuevas cápsides de aav y composiciones que las contienen. | |
MX2023001419A (es) | Vector viral adenoasociado para la expresion de glut1 y usos de este. | |
US20200268904A1 (en) | Wilson's Disease Gene Therapy | |
WO2023108029A3 (en) | Junctophilin-2 (jph2) gene therapy using aav vector | |
CO2024001148A2 (es) | Casetes de expresión optimizada para genoterapia | |
JP2020510433A5 (es) | ||
WO2023205767A3 (en) | B-cell lymphoma 2–associated anthanogene 3 (bag3) gene therapy using aav vector | |
CL2023001876A1 (es) | Proteínas de la cápside viral con especificidad para las células del tejido cardiaco | |
WO2024044691A3 (en) | Modified aav vectors for gene therapy | |
WO2023154763A3 (en) | Adeno-associated viral vector for glut1 expression and uses thereof | |
EA202091194A1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки |